Farmaceutica REMEDIA S.A.

BVB:RMAH Stock Report

Market Cap: RON 62.7m

Farmaceutica REMEDIA Management

Management criteria checks 1/4

Farmaceutica REMEDIA's CEO is Valentin-Norbert Tarus, appointed in Jan 2019, has a tenure of 6.33 years. directly owns 82.15% of the company’s shares, worth RON51.48M. The average tenure of the management team and the board of directors is 6.3 years and 2 years respectively.

Key information

Valentin-Norbert Tarus

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure6.3yrs
CEO ownership82.2%
Management average tenure6.3yrs
Board average tenure2yrs

Recent management updates

Recent updates

Farmaceutica REMEDIA's (BVB:RMAH) Dividend Will Be Reduced To RON0.04

Mar 23
Farmaceutica REMEDIA's (BVB:RMAH) Dividend Will Be Reduced To RON0.04

Farmaceutica REMEDIA's (BVB:RMAH) Soft Earnings Are Actually Better Than They Appear

Mar 06
Farmaceutica REMEDIA's (BVB:RMAH) Soft Earnings Are Actually Better Than They Appear

Returns At Farmaceutica REMEDIA (BVB:RMAH) Are On The Way Up

Mar 04
Returns At Farmaceutica REMEDIA (BVB:RMAH) Are On The Way Up

Farmaceutica REMEDIA's (BVB:RMAH) Returns On Capital Are Heading Higher

Mar 07
Farmaceutica REMEDIA's (BVB:RMAH) Returns On Capital Are Heading Higher

Returns Are Gaining Momentum At Farmaceutica REMEDIA (BVB:RMAH)

Aug 18
Returns Are Gaining Momentum At Farmaceutica REMEDIA (BVB:RMAH)

We Like These Underlying Return On Capital Trends At Farmaceutica REMEDIA (BVB:RMAH)

Mar 23
We Like These Underlying Return On Capital Trends At Farmaceutica REMEDIA (BVB:RMAH)

Does Farmaceutica REMEDIA (BVB:RMAH) Deserve A Spot On Your Watchlist?

Feb 16
Does Farmaceutica REMEDIA (BVB:RMAH) Deserve A Spot On Your Watchlist?

Is There More To The Story Than Farmaceutica REMEDIA's (BVB:RMAH) Earnings Growth?

Jan 15
Is There More To The Story Than Farmaceutica REMEDIA's (BVB:RMAH) Earnings Growth?

Is Farmaceutica REMEDIA S.A.'s (BVB:RMAH) Recent Performance Tethered To Its Attractive Financial Prospects?

Dec 16
Is Farmaceutica REMEDIA S.A.'s (BVB:RMAH) Recent Performance Tethered To Its Attractive Financial Prospects?

Should You Invest In Farmaceutica REMEDIA (BVB:RMAH)?

Nov 18
Should You Invest In Farmaceutica REMEDIA (BVB:RMAH)?

CEO

Valentin-Norbert Tarus (71 yo)

6.3yrs
Tenure

Mr. Valentin-Norbert Tarus has been President of Board of Administration of Farmaceutica Remedia SA since March 12, 2007 and serves as its General Manager since 2019. His first work experiences were in the...

Leadership Team

NamePositionTenureCompensationOwnership
Valentin-Norbert Tarus
President of Board of Administrators & GM6.3yrsno data82.15%
RON 51.5m
Elena Codrean
Chief Financial Officer6.3yrsno datano data
Florin Lupas
Administrative Manager8.1yrsno datano data
Florin Cadia
Investor Relations Director2yrsno datano data
Diana Neagu
Marketing Manager6.3yrsno datano data
Cristina Radu
HR Director5.1yrsno datano data
Cristian Plocon
Executive Non-Independent Administratorno datano datano data
6.3yrs
Average Tenure
47yo
Average Age

Experienced Management: RMAH's management team is seasoned and experienced (6.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Valentin-Norbert Tarus
President of Board of Administrators & GM18.2yrsno data82.15%
RON 51.5m
Cristian Plocon
Executive Non-Independent Administrator2yrsno datano data
Lucian-Valentin Codreanu
Independent Member of the Board of Administrators1yrno datano data
2.0yrs
Average Tenure
55yo
Average Age

Experienced Board: RMAH's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/20 15:00
End of Day Share Price 2025/05/20 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Farmaceutica REMEDIA S.A. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Virgil LivanovFairwind Consulting